Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemiaStephan Stilgenbauer, John F. Seymour, Eugen Tausch et al.|Blood Advances|2024Cited by 13
LBA1 | THE BENEFIT OF POLA‐R‐CHP IN DLBclass‐DEFINED MOLECULAR SUBSETS OF NEWLY DIAGNOSED DLBCL IN THE POLARIX TRIALEleonora Calabretta, Margaret A. Shipp, Maria C. Palazzo et al.|Hematological Oncology|2025Cited by 9